Halia Therapeutics to Attend BIO Convention and EHA Congress

Halia Therapeutics, a clinical-stage biopharmaceutical company based in Lehi, Utah, is making strides in the field of anti-inflammatory treatments. The company has announced its active participation in two prominent upcoming events: the BIO International Convention in San Diego from June 3-6, 2024, and the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain, from June 13-16, 2024.

At the EHA 2024 Congress, Halia's Chief Medical Officer, Dr. Margit Janat-Amsbury, will present a poster titled "Trial In Progress: Phase II Study of the NLRP3 Inflammasome & Myddosome Inhibitor HT-6184 in Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS)." This presentation will highlight early data from an ongoing Phase IIa clinical trial assessing the safety, efficacy, and pharmacodynamics of HT-6184 in MDS patients. This reflects Halia's commitment to advancing treatments for chronic inflammatory conditions.

Dr. Janat-Amsbury emphasized the promise shown by HT-6184 in initial trials, stating, "We are thrilled to share preliminary results from our Phase II study evaluating our lead asset HT-6184 in MDS patients. Initial data are encouraging, and we are confident that we will be able to advance the development of HT-6184, bringing a much-needed therapeutic option for those affected by this challenging condition.” This underscores Halia's dedication to exploring the full potential of HT-6184 in improving patient outcomes across various therapeutic areas through NLRP3-inhibition.

In addition to presenting at EHA 2024, Halia's leadership team, including President and CEO Dr. David J. Bearss, Chief Operating Officer Jared Bearss, MBA, and Chief Medical Officer Dr. Margit Janat-Amsbury, will be available for meetings with registered attendees at the BIO 2024 convention. These meetings can be scheduled through the event’s partnering system.

Halia Therapeutics is focused on discovering and developing novel therapeutics to improve the lives of patients suffering from chronic inflammatory and neurodegenerative diseases. Their lead candidate, HT-6184, is a novel NEK7/NLRP3 inhibitor that has successfully completed a Phase I study. This study evaluated the safety and tolerability of HT-6184 when administered as single or multiple oral doses at escalating levels in healthy volunteers. Halia has also initiated two Phase II trials to further examine the efficacy of HT-6184 in treating lower-risk myelodysplastic syndromes (LR-MDS) and investigating its effects on post-procedure diagnostic biomarkers of inflammation and pain.

Halia's pioneering efforts are crucial in addressing unmet medical needs, particularly in chronic inflammatory disorders. The positive preliminary data from their ongoing clinical trials bolster the company’s vision of delivering innovative and effective therapies to patients worldwide.

The company's headquarters are located in Lehi, Utah. Further details about Halia Therapeutics and updates on their clinical trials can be accessed through their official channels.

Dr. Margit Janat-Amsbury's presentation and the ongoing engagements at the BIO and EHA 2024 events highlight Halia Therapeutics' proactive role in the biopharmaceutical industry and their commitment to enhancing therapeutic options for complex conditions like MDS. Their ongoing research and development efforts aim to offer new hope to patients affected by chronic and debilitating diseases.